Table 8.
Catheter ablation of ventricular arrhythmias in cardiac sarcoidosis
| Study | N | LVEF, % | Concurrent immunosuppressive therapy, n (%) | VTs induced, mean ± SD | Mapping, Endo n/Epi n | Ablation, Endo n/Epi n | Patients undergoing repeated procedures, n (%) | VT recurrence, n (%) | VT burden decrease, n (%) | Major complications | Follow‐up, mo |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Koplan et al. (S9.12.26) | 8 | 35 ± 15 | 5 (63) | 4 ± 2 | 6/2 | 8/2 | 1 (13) | 6 (75) | 4 (44) | NR | 6 |
| Jefic et al. (S9.12.15) | 9 | 42 ± 14 | 8 (89) | 5 ± 7 | 8/1 | NR | 3 (33) | 4 (44) | 9 (100) | NR | 20 |
| Naruse et al. (S9.12.24) | 14 | 40 ± 12 | 12 (86) | 3 ± 1 | 14/0 | 14/0 | 4 (29) | 6 (43) | NR | NR | 33 |
| Dechering et al. (S9.12.12) | 8 | 36 ± 19 | NR | 4 ± 2 | NR | NR | NR | 1 (13) | 7 (88) | NR | 6 |
| Kumar et al. (S9.12.27) | 21 | 36 ± 14 | 12 (57) | Median 3 (range 1–8) | 21/8 | 21/5 | 11 (52) | 15 (71) | 16 (76) | 4.7% | 24 |
| Muser et al. (S9.12.25) | 31 | 42 ± 15 | 22 (71) | Median 3 (range 1–5) | 31/11 | 31/8 | 9 (29) | 16 (52) | 28 (90) | 4.5% | 30 |
Abbreviations: LVEF, left ventricular ejection fraction; N, number; NR, not reported; VT, ventricular tachycardia.